Home | Find A Doctor | Contact Us


RTOG 0436: A Phase III Trials Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who Are Treated Without Surgery

Principal Investigator: Peter Kozuch, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai West


Continuum Cancer Research Program
(212) 844-6286


The standard treatment for people with esophageal cancer who don’t have surgery is a combination of chemotherapy drugs called cisplatin and paclitaxel (chemotherapy).  Radiation therapy is also given.  Research want to know if adding a chemotherapy drug called cetuximab might help treat esophageal cancer.  Cetuximab is currently given for colorectal cancer and head and neck cancer.  Subjects In this study will receive either cispatin, paclitaxel, and radiation or cispatin, paclitaxel, and radiation and cetuximab.

Eligibility Participants:

  1. Diagnosis of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction.
  2. Subjects must be at least 18 years old
  3. Subjects with celiac, perigastric, mediastinal, supraclavicular adenopathy, or cervical esophageal carcinoma are eligible.

Please call for more information



Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System